View clinical trials related to Dravet Syndrome.
Filter by:The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy